POSTER: AML-474 γ9δ2 T-Cell Activation (γδTCA) With ICT01 and Azacitidine-Venetoclax (Aza-Ven) Induces High Rates of Complete Remission (CR) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML): Preliminary Results of the Phase 1/2 Study EVICTION | Publicación